Peptic ulcer Peptic ulcer
Conditions
Interventions
Geranylgeranyl acetone,
an acyclic polyisoprenoid compound ,Placebo
Active Comparator Drug,Placebo Comparator No treatment
teprenone 150 mg/day,Placebo
Sponsors
Gastrohepatology Unit, Department of Internal Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who were Helicobacter pylori negative at screening and who required continuous medications with LDA (75-325 mg/day) for at least 4 weeks after participation in the study, regardless of history of LDA therapy, and that they were aged 20 years or older
Exclusion criteria
Exclusion criteria: Presence of peptic ulcer detected on endoscopy at the start of treatment; previous gastrectomy or vagotomy; treatment with a PPI or H2RA within 4 weeks before the administration of study medication; treatment with a NSAID or corticosteroid within 4 weeks before the administration of study medication; serious liver disease, serious renal disease, serious cardiac disease and/or serious blood dyscrasia; allergy or previous experience of an adverse reaction to teprenone; pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence rate of peptic ulcer 4 weeks Gastroscopy | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence rate of gastritis,, the change of GSRS 4 weeks Gastroscopy,Change of the modifed Lanza score 4 weeks Gastroscopy,Change of GSRS 4 weeks Questionnaire | — |
Countries
Thailand
Contacts
Public ContactTaned Chitapanarux
Chiang Mai University
Outcome results
None listed